Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.09(+0.24%)
Hang Seng
17,941.78
-170.85(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,048.46
-144.85(-0.22%)
CMC Crypto 200
1,371.24
-46.63(-3.29%)

PFE Jul 2024 32.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0400

-0.0200

(-33.33%)

As of 01:42PM EDT. Market open.

Loading interactive chart…

Zacks
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Zacks
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Business Wire
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
NEW YORK, June 14, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.